Cargando…
iRECIST and atypical patterns of response to immuno-oncology drugs
With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyper...
Autores principales: | Ramon-Patino, Jorge Luis, Schmid, Sabine, Lau, Sally, Seymour, Lesley, Gaudreau, Pierre-Olivier, Li, Janice Juan Ning, Bradbury, Penelope Ann, Calvo, Emiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207898/ https://www.ncbi.nlm.nih.gov/pubmed/35715004 http://dx.doi.org/10.1136/jitc-2022-004849 |
Ejemplares similares
-
iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020) -
Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021) -
Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021) -
Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021) -
Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
por: Kim, Nari, et al.
Publicado: (2022)